Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia

Curr Pharm Des. 2018;24(31):3597-3598. doi: 10.2174/138161282431181224144112.

Authors

Michael Doumas^{1

2}, Konstantinos Imprialos¹, Konstantinos Stavropoulos¹, Vasilios G Athyros¹

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
² George Washington University, Washington, DC; and Veteran Affairs Medical Center, Washington, DC, United States.

PMID: 30642238
DOI: 10.2174/138161282431181224144112

No abstract available

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
Hyperlipoproteinemia Type II / drug therapy*
Hyperlipoproteinemia Type II / epidemiology*
Hyperlipoproteinemia Type II / genetics
Mutation
Receptors, LDL / antagonists & inhibitors*
Receptors, LDL / genetics

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDLR protein, human
Receptors, LDL